AG
SNDX icon

Algert Global’s Syndax Pharmaceuticals SNDX Stock Holding History

Algert Global’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23M Buy
1,051,465
+122,897
+13% +$2.56M 0.27% 64
2026
Q1 		$21.7M Buy
928,568
+480
+0.1% +$10.4K 0.33% 49
2025
Q4 		$19.5M Sell
928,088
-2,678
-0.3% -$46.7K 0.3% 58
2025
Q3 		$14.3M Sell
930,766
-90,514
-9% -$1.18M 0.24% 96
2025
Q2 		$9.56M Buy
1,021,280
+136,680
+15% +$1.5M 0.2% 140
2025
Q1 		$10.9M Buy
884,600
+98,968
+13% +$1.4M 0.27% 82
2024
Q4 		$10.4M Buy
785,632
+310,634
+65% +$5.32M 0.24% 99
2024
Q3 		$9.14M Buy
474,998
+42,870
+10% +$886K 0.25% 95
2024
Q2 		$8.87M Buy
432,128
+6,455
+2% +$135K 0.3% 61
2024
Q1 		$10.1M Sell
425,673
-102,484
-19% -$2.29M 0.4% 35
2023
Q4 		$11.4M Buy
528,157
+71,938
+16% +$1.11M 0.46% 13
2023
Q3 		$6.62M Buy
456,219
+202,588
+80% +$3.83M 0.31% 67
2023
Q2 		$5.31M Buy
253,631
+167,660
+195% +$3.49M 0.23% 103
2023
Q1 		$1.82M Buy
85,971
+8,191
+11% +$204K 0.09% 381
2022
Q4 		$1.98M Buy
77,780
+28,880
+59% +$674K 0.11% 300
2022
Q3 		$1.18M Sell
48,900
-5,814
-11% -$130K 0.07% 471
2022
Q2 		$1.05M Buy
54,714
+13,180
+32% +$220K 0.08% 448
2022
Q1 		$722K Buy
41,534
+9,948
+31% +$168K 0.05% 666
2021
Q4 		$691K Buy
+31,586
New +$584K 0.09% 420
2021
Q2 		– Sell
-9,550
Closed -$214K – 520
2021
Q1 		$214K Sell
9,550
-18,020
-65% -$407K 0.07% 366
2020
Q4 		$613K Buy
27,570
+8,440
+44% +$175K 0.17% 191
2020
Q3 		$282K Buy
19,130
+8,350
+77% +$127K 0.09% 268
2020
Q2 		$160K Sell
10,780
-11,800
-52% -$180K 0.05% 346
2020
Q1 		$248K Sell
22,580
-3,000
-12% -$28.2K 0.1% 278
2019
Q4 		$225K Buy
25,580
+8,110
+46% +$59.6K 0.07% 300
2019
Q3 		$131K Buy
17,470
+1,600
+10% +$14.6K 0.05% 308
2019
Q2 		$148K Buy
+15,870
New +$116K 0.05% 302
2018
Q3 		– Sell
-73,499
Closed -$516K – 382
2018
Q2 		$516K Buy
+73,499
New +$721K 0.11% 241

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Algert Global's SNDX Position: Q2 2026 in Review

Algert Global increased its Syndax Pharmaceuticals (SNDX) stake by 13% in Q2 2026, buying an estimated $2.56M and bringing the position to 1,051,465 shares worth $23M. The position accounts for 0.27% of the portfolio, ranked #64.

Algert Global first reported a position in SNDX in Q2 2018 and has held it in 28 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Algert Global held 1,051,465 shares of Syndax Pharmaceuticals worth $23M as of Q2 2026.
  • Algert Global bought 122,897 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.56M.
  • Syndax Pharmaceuticals made up 0.27% of Algert Global's portfolio in Q2 2026, its #64 holding.
  • Algert Global first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 28 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.